Cingulate (CINGW) Cash & Equivalents (2021 - 2026)
Cingulate's (CINGW) quarterly Cash & Equivalents came in at $28.4 million in Q2 2026, up 159.31% quarter-over-quarter from $11.0 million in Q4 2025.
Analysis
Cingulate (CINGW) Cash & Equivalents (2021 - 2026) Analysis & Trends
Cingulate (CINGW) has reported Cash & Equivalents for 6 consecutive years, with $28.4 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Cash & Equivalents changed N/A year-over-year to $28.4 million; the trailing twelve-month figure through Jun 2026 stood at $28.4 million (changed N/A YoY), and the FY2025 full-year result was $11.0 million, down 10.3% from the prior year.
- Cash & Equivalents advanced to $28.4 million in Q2 2026 per CINGW's latest filing, from $11.0 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $28.4 million in Q2 2026 and bottomed at $52416.0 in Q4 2023.
- Historically, Cash & Equivalents has averaged $7.4 million across 5 years, with a median of $7.2 million in 2022.
- The sharpest annual moves came in 2023 and 2024: Cash & Equivalents tumbled 99.02% in 2023, then jumped 23196.93% in 2024.
- Over 5 years, Cash & Equivalents stood at $5.4 million in 2022, then sank by 99.02% to $52416.0 in 2023, then surged by 23196.93% to $12.2 million in 2024, then dropped by 10.3% to $11.0 million in 2025, then surged by 159.31% to $28.4 million in 2026.
- According to Business Quant data, Cash & Equivalents over the past three periods registered $28.4 million, $11.0 million, and $6.1 million for Q2 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.10 Bn | 625.34 Bn | 17.26 Bn | 20.42 Bn |
| 2 | AbbVie | 441.68 Bn | 435.11 Bn | 12.70 Bn | 6.57 Bn |
| 3 | Merck | 366.62 Bn | 359.48 Bn | 12.21 Bn | 6.85 Bn |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn | 7.62 Bn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | 976.00 Mn |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | 7.38 Bn |
| 7 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | 815.44 Mn |
| 8 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | 3.98 Bn |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | 1.80 Bn |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | 28.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 28.40 Mn |
| Dec 31, 2025 | 10.95 Mn |
| Sep 30, 2025 | 6.12 Mn |
| Mar 31, 2025 | 9.52 Mn |
| Dec 31, 2024 | 12.21 Mn |
| Sep 30, 2024 | 10.04 Mn |
| Jun 30, 2024 | 400,000.00 |
| Mar 31, 2024 | 1.11 Mn |
| Dec 31, 2023 | 52,416.00 |
| Sep 30, 2023 | 1.99 Mn |
| Jun 30, 2023 | 349,831.00 |
| Mar 31, 2023 | 1.74 Mn |
| Dec 31, 2022 | 5.36 Mn |
| Sep 30, 2022 | 9.80 Mn |
| Jun 30, 2022 | 8.20 Mn |
| Mar 31, 2022 | 12.61 Mn |
| Dec 31, 2021 | 16.49 Mn |